Back to News
Jun 8, 2026 4:00 PM

AstraZeneca Reports Significant Proteinuria Reduction With Ultomiris In Rare Kidney Disease

AstraZeneca Plc. (NASDAQ:AZN) said its Phase 3 I CAN trial evaluating Ultomiris (ravulizumab) in adults with immunoglobulin A nephropathy (IgAN) at risk of disease progression met a prespecified interim endpoint.

The study showed a statistically significant and clinically meaningful reduction in proteinuria compared with placebo at week 34.

AstraZeneca’s Ultomiris Cuts Proteinuria

According to the interim analysis, patients treated with Ultomiris achieved a 46.6% reduction in 24-hour urine protein creatinine ratio (UPCR) from baseline, compared with a 5.6% reduction in the placebo group.

The placebo-adjusted treatment effect was 43.4%, with the result reaching statistical significance (p<0.0001).

Read Also:

AstraZeneca Highlights Sustained Survival Benefit In Advanced Breast Cancer Study

AstraZeneca Reports Early And Sustained Response

The company said ...